Ask AI
KRAS G12C Therapies in NSCLC
Advancing KRAS G12C-Targeted Therapies in NSCLC: Current Evidence and Future Directions

Released: March 10, 2026

Activity

Progress
1
Course Completed

In this episode, Dr Paz-Ares and Dr Christine Bestvina discuss the evolving role of KRAS G12C inhibitors in non-small-cell lung cancer (NSCLC), including:

  • Clinical outcomes and limitations of first-generation KRAS G12C inhibitors
  • Key unmet needs, including primary and acquired resistance
  • Emerging strategies, including next-generation inhibitors and combination approaches with chemotherapy and immunotherapy